

## **RHINOMED'S NEW HIGH COMFORT NASAL SWAB SUCCESSFULLY REGISTERED WITH AUSTRALIAN TGA**

**25 November 2020, Melbourne Australia.**

Rhinomed Limited (ASX:RNO OTCQB:RHNMF), a leader in nasal airway and respiratory technology, has successfully registered its easy to use, high load capturing, comfortable nasal swab with the Australian Therapeutic Goods Administration (TGA) as a Class 1 device.

The new swab can comfortably collect samples from both nostrils simultaneously to test for the presence of upper respiratory tract diseases including influenza and coronavirus including SARS-CoV-2. The unique design not only enables a larger sample to be collected but also opens up the opportunity for mass, high frequency testing; a critical strategic response to pandemics such as Covid-19.

This news follows last week's announcement that Rhinomed had successfully registered this novel nasal swab with the US FDA as a Class 1 device to collect samples.

The issue of the Australian Register of Therapeutic Goods (ARTG) number confirms the device has been included in the ARTG and therefore Rhinomed may commence supply of the device immediately.

The new nasal swab builds on the company's expertise as a world-leading developer of nasal devices. Rhinomed's existing FDA and TGA registered nasal products; Mute (anti-snoring), Pronto (anti-nasal-congestion and sleep improvement) and Turbine (improved breathing for sports) have been worn comfortably and safely since 2016. Rhinomed sells these products in over 20,000 pharmacies worldwide.

Rhinomed's novel nasal swab is designed to be:

- Less invasive and more comfortable than standard nasopharyngeal swabs;
- Unique as it collects sample from both nostrils simultaneously, doubling the sample volume collection potential;
- Able to collect samples from a far greater surface area of the nose than normal swabs;
- Designed to fit into existing vials and work with existing pathology workflows;
- Able to be self-administered easily, anywhere, reducing the risk of infection of healthcare workers,
- Able to be used by a large number of people, everyday; and
- Provide improved repeatability and reliability of swabbing.

The Company is now rapidly scoping out local and foreign manufacturing, assessing additive manufacturing (3D printing) solutions and advancing discussions with potential commercial partners. Further details on the clinical and commercial program will be announced in due course.

This announcement has been authorised for release by the Board.

**Media Enquiries**

Michael Johnson, CEO & Director

+61 (03) 8416 0900

[mjohnson@rhinomed.global](mailto:mjohnson@rhinomed.global)

Follow us on **Twitter** @rhinomedceo and @theturbinecom

Rudi Michelson, Monsoon Communications

+61 (0)411 402 737

[rudim@monsoon.com.au](mailto:rudim@monsoon.com.au)

**About Rhinomed Limited (ASX: RNO, OTCQB:RHNMF)**

Rhinomed Limited is a Melbourne-based ASX-listed airway technology company that has developed a novel nasal and respiratory technology platform.

With its initial product Turbine, Rhinomed has established a leading position in emphasizing the role of breathing in sport and exercise. With its Mute variant, the company has also entered the sleep sector to tackle the global snoring market, while its third product, the Pronto range, tackles nasal congestion and sleep disturbance issues. The company is developing applications for the delivery of medical cannabis and for conditions including anxiety, pain, allergies, nausea, anxiety and coughs and colds.

Rhinomed's devices are sold in over 20,000 stores worldwide including Walgreens, CVS, Boots and online with Amazon; and are approved in major markets including the US, Europe, Canada and Australia.